Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expa

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and r

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen'

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raise

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Thera

Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch

U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, follo

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and main

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutic

First approved treatment for thyroid eye disease (TED) with labeling that includes data for both act

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compa

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or t

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Co

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a prim

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compan

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are up on Tuesday as the company announced positive

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW c

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f

  On Friday, 1043 companies hit new 52-week lows.